Teva

Teva 'disappointed' by Irish consultants' boycott of its pharmaceuticals, company tells 'Post'

Teva told the Post it remains committed to working constructively with healthcare professionals across Ireland and to supporting patients through the "consistent supply of high-quality medicines."

The logistics center of Teva Pharmaceutical Industries in Shoham
In January, Israel’s Ministry of Defense signed a multi-year contract with Semiconductor Devices valued at approximately $115 million (NIS 380 million).

The curse of being Israel's most valuable company

The logistics center of Teva Pharmaceutical Industries in Shoham

Mega deal: Teva acquires Emalex for approximately $900 million

Noam Zilbershtain, senior vice president and general manager, HP Indigo; Adi Soffer Teeni, CEO of Meta Israel, vice president and member of the EMEA leadership team; and Karin Mayer Rubinstein, CEO and president of IATI.

IATI CEOs Forum meets in Kiryat Gat to discuss multinational industry resilience


Teva gets approval in China for Huntington's disease treatment

Teva’s CEO Kare Schultz said the drug would be priced somewhat lower in China than in the United States.

A building belonging to generic drug producer Teva, Israel's largest company with a market value of about $57 billion, is seen in Jerusalem

Teva's profit beats forecasts, shares jump

Shares in the world’s largest generic drugmaker jumped nearly 20% in late Tel Aviv trade as the company also reaffirmed its 2020 outlook, despite disruption to the global economy from the coronavirus

A building belonging to generic drug producer Teva, Israel's largest company with a market value of about $57 billion, is seen in Jerusalem

Teva donates potential coronavirus treatment to hospitals across the US

Hydroxychloroquine sulfate tablets are used against malaria, lupus erythematosus and rheumatoid arthritis but could be effective against COVID-19.

A building belonging to generic drug producer Teva, Israel's largest company with a market value of about $57 billion, is seen in Jerusalem

After turbulent years, Teva CEO Schultz forecasts stability

Teva completed its two-year major restructuring plan in 2019, reducing its cost base by over $3 billion and net debt by more than $9b.

Teva CEO Kåre Schultz at the Tel Aviv Stock Exchange, February 19, 2020

Teva's first ever National Forum for Bio-Innovators gathers in Tel Aviv

Researcher Hila Flayev has for years been conducting research on computational models of the coronavirus structure and interactions it can create.

Teva's first ever National Forum for Bio-Innovators gathers in Tel Aviv

Teva Naot launches store in Vancouver, Canada

In 2019, Teva Naot sold about 100,000 pairs of shoes in its stores and to retailers, and through the website in the Canadian market.

FROM RIGHT TO LEFT: Teva Naot CEO Michael Iluz, spokesmodel Dana Grotsky and owner Steve Lax

Teva’s proposed settlement could cost drugmaker pennies on the dollar

Israel-based Teva is looking to reach a nationwide settlement over its role in selling opioid painkillers, together with drugmaker Johnson & Johnson and the three largest U.S. drug distributors.

A building belonging to generic drug producer Teva, Israel's largest company with a market value of about $57 billion, is seen in Jerusalem

Teva shares surge amid hopes of $23 billion opioid claims settlement

Teva stocks also closed up 8.67% on the New York Stock Exchange on Monday amid growing optimism.

Pharmacist Jim Pearce fills a Suboxone prescription at Boston Healthcare for the Homeless Program in Boston

Opioid settlement talks fail with Teva, landmark trial expected Monday

After nearly 11 hours of negotiations, Pennsylvania Attorney General Josh Shapiro told reporters it was “profoundly disappointing” that local governments would not go along with a settlement.

A building belonging to generic drug producer Teva, Israel's largest company with a market value of about $57 billion, is seen in Jerusalem

Teva proposes $15 billion deal to settle opioid claims

The proposed settlement comes only days ahead of a landmark federal trial in Cleveland, Ohio, against the company and five drug distributors.

The CEO of Teva Pharmaceutical Industries Kare Schultz speaks during a news conference to discuss the company's 2019 outlooks in Tel Aviv, Israel February 19, 2019